Japan’s Ministry of Health, Labour and Welfare granted orphan drug designation for Sanofi’s investigational treatment for people living with chronic inflammatory demyelinating polyneuropathy (CIDP). This designation brings us one step closer to hopefully addressing the unmet need for patients living with #CIDP. Our goal is to help people live for the moment, not the disease. Read our press release ➡️ https://lnkd.in/e3SVkSnS
Congrats!
Congrats! 🎉
Great to see continued progress in addressing rare and underserved conditions!
C'est cool que le Japon avance sur ça, ça va changer des vies, j'imagine.
🚀 Exciting and amazing update!!!
This is an important step forward for those affected by CIDP. Advancing treatments like this can truly improve quality of life for patients facing this challenging condition.
Thanks for sharing
This is a meaningful step forward for people living with CIDP. Advancing riliprubart shows commitment to tackling complex neurological conditions with targeted science.